17-Jul-2020 - QIAGEN N.V.

Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement

Offer price increased

Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.

The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the acquisition agreement and Thermo Fisher’s intention to commence the offer. The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN’s issued and outstanding ordinary share capital at the end of the acceptance period on August 10, 2020, as well as a USD 95 million expense reimbursement to Thermo Fisher if the minimum acceptance threshold is not met.

The members of QIAGEN’s Supervisory Board and Managing Board have reaffirmed their unanimous support for the offer and their unanimous recommendation that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period, which has now been extended to August 10, 2020. Each of the members of the Supervisory Board and Managing Board has tendered or will tender all of their QIAGEN shares in the offer.

Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, said, “Industry dynamics have changed considerably in the past few months, creating tailwinds and headwinds for our businesses. Both of our companies are playing important roles in helping customers to battle the COVID-19 pandemic. After careful consideration, we’ve decided to increase our offer for QIAGEN to reflect the fair value of the business given the current environment. We remain confident that this transaction will create shareholder value and, importantly, provide meaningful benefits to our customers and society by combining our capabilities to combat infectious diseases and other healthcare issues. We continue to look forward to completing the transaction in the first half of 2021.”

“After carefully considering the updated offer by Thermo Fisher, QIAGEN’s Supervisory Board and Managing Board both unanimously recommend that shareholders accept this offer given that it reflects the improvements in our business performance and future prospects as a result of the coronavirus pandemic,” said Thierry Bernard, chief executive officer of QIAGEN N.V. “The rationale for this strategic step is stronger than ever, especially as the value of molecular testing becomes ever more evident. This combination is designed to enable QIAGEN employees and our portfolio of Sample to Insight solutions to have an even greater impact on society while also delivering significant cash value to our shareholders. We look forward to working closely with Thermo Fisher to successfully complete the transaction.”

QIAGEN shareholders who have already effectively accepted the offer by tendering their shares are not required to take further action in order to receive the increased offer price in accordance with the terms of the offer. Thermo Fisher’s tender offer statement on Schedule TO, including the offer document that is an exhibit thereto, and QIAGEN’s solicitation/recommendation statement on Schedule 14D-9 will be amended to reflect the revised terms of the transaction. The acceptance period is now scheduled to expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on August 10, 2020.

Facts, background information, dossiers
  • Thermo Fisher Scientific
  • Qiagen
  • acquisitions
More about Qiagen
  • News

    QIAGEN fully acquires NeuMoDx Molecular

    QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed ... more

    QIAGEN names Thierry Bernard as Chief Executive Officer

    QIAGEN announced that Thierry Bernard has been named Chief Executive Officer. Additionally, a Joint Meeting of the Supervisory Board and the Managing Board has resolved to propose Mr. Bernard, who has been with QIAGEN since 2015, for election as Chief Executive Officer and a Managing Direct ... more

    QIAGEN launches coronavirus test kit in Germany following derogation by BfArM

    QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, ... more

  • Companies

    QIAGEN GmbH

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN Instruments AG

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN N.V.

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

More about Thermo Fisher Scientific